



CMAC

**FUTURE MANUFACTURING
RESEARCH HUB**

A Rational Single Particle Design Approach Using an Acoustic Levitation System and X- Ray Tomography


Frederik Doerr

8th World Congress on Particle Technology

April 2018

- Motivation - Focus and Application
- Single Particle Experiments
 - Acoustic Levitation Setup
 - XRT: Hardware and Data Collection
 - Image Processing & Analysis
- **Experimental Results:**
 - Single Droplet Evaporation Experiments - *Characterisation of Liquid Evaporation, Solidification and Drying*
 - XRT: Formulated Metformin Particles - *Investigation of the final Particle Morphology*
- Single Particle Experiments - Link to Performance
- Conclusion

CMAC: Aim for integrated, continuous pharmaceutical MicroFactories supported by a predictive design framework to enable fast product and process development.



Process integration and control require a reliable characterisation of the manufacturing process and of a vast variety of pharmaceutical (intermediate) products with complex multi-dimensional solid state attributes.

Motivation: Control and Optimisation of Particles from Continuous Droplet Drying Platforms (e.g. Spray Drying)



→ Smallest Scale: Single Droplet Drying Experiments

Case Study: Formulated Particles for Controlled Release


Drug: Metformin Hydrochloride

BCS III, high water solubility, low permeability, tablets with high drug loads of up to 50 wt.-%

Excipients:

HPMC K100LV PH: hydrophilic matrix former

D-Mannitol: high crystallinity, low moisture uptake



Objective: Improve Particle Properties with potential impact on critical Quality Attributes


Manufacturability for Direct
Compaction




Dissolution and Drug Release



Evaporation and Solid Phase Formation



Investigation of
Particle Structure



Controlled Temperature, Humidity and Gaseous Flow

$$\text{D}^2\text{-law} \quad \left(\frac{d(t)}{2}\right)^2 = \left(\frac{d_0}{2}\right)^2 - \kappa t$$

$$\text{with} \quad \kappa = 8D_{AB} \frac{\rho_{\text{gas}}}{\rho_{\text{liquid}}} \cdot \ln\left(\frac{1 - Y_{\infty}}{1 - Y_S(T)}\right)$$



Single droplet evaporation experiments in an acoustic levitator used as a particle design platform. Investigation of Solid Phase Formation.



Scanning

Acquiring raw Data (2D, 14bit images) from sample.



Reconstruction

Transformation of 2D projections into a 3D-reconstruction of the sample





Analysis / 3D Rendering

Image analysis to extract desired sample information. 3D volume rendering to produce an interactive 3D model for visualisation.



SkyScan 2211 (nanoCT)

Geometric magnification



X-ray Source

Accelerating voltage: 20 - 190kV




Emission power: 4 W (Be window)

Transmission Target material: Tungsten



Beam spot size: nanomode 900nm, micromode 2um

Detector


- 11Mp CCD-Sensor
- CCD temperature stabilization
- central 4000x2670 pixel, 9um /pixel
- 14bit digitalization, 70dB dynamic range



a) Raw cross-sections, (b) binary images, (c) particle ROI, (d) particle porosity, (e) particle concave volume



■ Surface Layers: Metformin, Mannitol, **K100LV**
■ Core Layers: **Metformin, Mannitol, K100LV**



$$\rho = \frac{m}{V} = \frac{c_0 \cdot V_{\text{Droplet},0}}{V_{CT}}$$

($\rho = 1.36 \pm 0.02 \text{ g cm}^{-3}$)

From Vehring et.al for $Pe < 20$:

$$E = \frac{c_s}{c_m} = 1 + \frac{Pe}{5} + \frac{Pe^2}{100} + \frac{Pe^3}{4000}$$

with $Pe = \frac{\kappa}{8D_s}$

Diffusion Coefficients in Water

$$D_{K100LV} = 4.621 \cdot 10^{-11} \text{ m}^2 \cdot \text{s}^{-1}$$




$$D_{MET} = 1.17 \cdot 10^{-9} \text{ m}^2 \cdot \text{s}^{-1}$$

$$D_{MAN} = 7.56 \cdot 10^{-10} \text{ m}^2 \cdot \text{s}^{-1}$$

Single Droplet Evaporation Experiments Formulated Metformin Hydrochloride

Formulations of Metformin HCl (18.75 mg/mL) with D-Mannitol (18.75 mg/mL) and increasing additions of HPMC K100LV:

- (MS_0) + 0.000 mg/mL (■ Volume, □ Temperature)
- - - (MS_1) + 0.375 mg/mL (● Volume, ○ Temperature)
- (MS_4) + 4.500 mg/mL (▲ Volume, △ Temperature)



- The addition of HPMC K100LVPH causes a significant reduction of the droplet evaporation and drying kinetics even at solid mass concentrations of less than 1wt.-% (b).
- The reduction in the evaporative mass transfer causes a delay of the solid skin formation despite higher solute concentrations.









(MS_0) - wt.-%

(MS_1) 0.99 wt.-%

(MS_2) 1.96 wt.-%



(MS_3) 5.66 wt.-%

(MS_4) 10.71 wt.-%




Formulated Metformin HCl particles with increasing HPMC K100LV Solid Mass Fraction [wt.-%]

Particle Solid Phase
Particle Concave Surface Volume
 Particle Porosity






(MS_0) - wt.-% (MS_1) 0.99 wt.-% (MS_2) 1.96 wt.-% (MS_3) 5.66 wt.-% (MS_4) 10.71 wt.-%



Metformin HCl
D-Mannitol (1:1,w:w)
+ HPMC K100LV
Solid Mass [wt.-%]




Particle Volume Distribution


- Solid Phase Volume
- Porosity Volume
- Concave Volume

Particle Shape


- Aspect Ratio
- Sphericity



(MS_0) - wt.-% (MS_1) 0.99 wt.-% (MS_2) 1.96 wt.-% (MS_3) 5.66 wt.-% (MS_4) 10.71 wt.-%



Metformin HCl
D-Mannitol (1:1,w:w)
+ HPMC K100LV
Solid Mass [wt.-%]



Particle Volume Distribution


- Solid Phase Volume
- Porosity Volume**
- Concave Volume

Particle Shape


- Aspect Ratio
- Sphericity



(MS_0) - wt.-% (MS_1) 0.99 wt.-% (MS_2) 1.96 wt.-% (MS_3) 5.66 wt.-% (MS_4) 10.71 wt.-%



Metformin HCl
D-Mannitol (1:1,w:w)
+ HPMC K100LV
Solid Mass [wt.-%]




Particle Volume Distribution

- Solid Phase Volume
- Porosity Volume
- Concave Volume**



Particle Shape

- Aspect Ratio
- Sphericity



Aspect Ratio (Ellipsoidal Shape Fit): $\frac{c}{a} = \frac{\text{Max Principal Axis}}{\text{Min Principal Axis}}$

Sphericity (Wadell): $\Psi = \frac{\pi^{\frac{1}{3}} (6V_p)^{\frac{2}{3}}}{A_p}$



Metformin HCl : D-Mannitol (1:1,w:w) + HPMC K100LV Solid Mass Fraction [wt.-%]

	n	Aspect Ratio	Sphericity
MS_0	7	1.20 ± 0.05	0.95 ± 0.04
MS_1	8	1.96 ± 0.52	0.90 ± 0.05
MS_2	3	1.93 ± 0.28	0.89 ± 0.05
MS_3	5	2.49 ± 0.35	0.80 ± 0.05
MS_4	5	2.52 ± 0.20	0.73 ± 0.03


Particle Volume Distribution

Solid Phase Volume
Porosity Volume
Concave Volume

Particle Shape

Aspect Ratio
Sphericity


1) Particle Compaction




PURDUE
UNIVERSITY

Acknowledgement: Prof Marcial Gonzalez, Ankit Agarwal
I2APM Placement October - November 2017

2) Particle Dissolution



- We demonstrated the use of Acoustic Levitation and X-ray Tomography to evaluate the particle design space for formulated Metformin Hydrochloride Particles with increasing additions of HPMC K100LV PH.
- The combined SAL & XRT platform allows an investigation of the evaporation and drying kinetics with an in-depth non-destructive characterisation of the final particle morphology working on a single droplet/particle scale with minimized material consumption.
- Future work will aim to link information on the particle formation process and its final structural properties to critical quality attributes with a potential impact on performance under direct compaction and during dissolution.



Acknowledgements

Supervision & Co-Authors

- Dr Iain Oswald
- Prof Alastair Florence

I2APM Collaboration

- Prof Marcial Gonzalez, Ankit Agarwal, Yasasvi Bommireddy (Purdue University)

Collaborations & PhD Support

- Dr John Robertson (Senior Research Fellow)
- National Facility Team

Funding

CMAC DTC (Grant Ref: EP/K503289/1), EPSRC Future Continuous Manufacturing and Advanced Crystallisation Research Hub (Grant Ref EP/P006965/1), CMAC National Facility (UKRPIF Grant Ref HH13054)

This work was supported by:





CMAC

**FUTURE MANUFACTURING
RESEARCH HUB**

www.cmac.ac.uk